S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
S&P 500   3,977.53
DOW   32,432.08
QQQ   308.76
Should You Buy Before the Ex-Dividend Date or Wait?
Bank Accounts: Frozen! (Ad)
Dividends, Short-Term Pain, but Long-Term Gain?
Can Carnival Cruise Lines Set Sail For New Highs? 
Bank Accounts: Frozen! (Ad)
BioNTech Is Ripe For A Rebound In 2023 
If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Bank Accounts: Frozen! (Ad)
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
NASDAQ:VRNA

Verona Pharma - VRNA Stock Forecast, Price & News

$20.35
-0.28 (-1.36%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$20.32
$21.10
50-Day Range
$18.06
$23.69
52-Week Range
$3.41
$26.44
Volume
347,699 shs
Average Volume
500,259 shs
Market Capitalization
$1.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.33

Verona Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
44.1% Upside
$29.33 Price Target
Short Interest
Healthy
2.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.18mentions of Verona Pharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$2.79 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.90) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

404th out of 995 stocks

Pharmaceutical Preparations Industry

185th out of 482 stocks


VRNA stock logo

About Verona Pharma (NASDAQ:VRNA) Stock

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
H.C. Wainwright Reaffirms Their Buy Rating on Verona Pharma (VRNA)
Modern Day Options Trading For Beginners!
These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. pixel
Earnings Preview For Verona Pharma
Verona (VRNA) to Report Q4 Earnings: What's in the Cards?
4 Drug Stocks That More Than Doubled This Year
See More Headlines
Receive VRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.

VRNA Company Calendar

Last Earnings
3/07/2023
Today
3/28/2023
Next Earnings (Estimated)
5/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VRNA
Fax
N/A
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.33
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+44.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-68,700,000.00
Pretax Margin
-14,944.98%

Debt

Sales & Book Value

Annual Sales
$460,000.00
Book Value
$3.05 per share

Miscellaneous

Free Float
72,674,000
Market Cap
$1.54 billion
Optionable
Not Optionable
Beta
0.13

Key Executives

  • Dr. David S. ZaccardelliDr. David S. Zaccardelli (Age 57)
    Pres, CEO & Exec. Director
    Comp: $627.27k
  • Mr. Mark W. HahnMr. Mark W. Hahn (Age 59)
    Chief Financial Officer
    Comp: $639.08k
  • Dr. Kathleen A. Rickard (Age 64)
    Chief Medical Officer
    Comp: $562.38k
  • Ms. Claire Louise Poll L.C.S.W. (Age 55)
    B.A., B Juris, LLB, ASIA, Gen. Counsel
  • Ms. Victoria Stewart
    Director of Communications
  • Mr. Matthew Casbon
    VP of Sales, Marketing & Training
  • Ms. Ostra Jewell
    Sr. VP of HR
  • Dr. Peter Spargo (Age 60)
    Sr. VP of Chemistry Manufacturing & Controls
  • Dr. Tara Rheault M.P.H. (Age 45)
    Ph.D., Sr. VP of R&D
  • Ms. Nina Church
    Exec. Director of Global Clinical Devel.













VRNA Stock - Frequently Asked Questions

Should I buy or sell Verona Pharma stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRNA shares.
View VRNA analyst ratings
or view top-rated stocks.

What is Verona Pharma's stock price forecast for 2023?

6 equities research analysts have issued 12-month price objectives for Verona Pharma's stock. Their VRNA share price forecasts range from $27.00 to $32.00. On average, they anticipate the company's stock price to reach $29.33 in the next year. This suggests a possible upside of 44.1% from the stock's current price.
View analysts price targets for VRNA
or view top-rated stocks among Wall Street analysts.

How have VRNA shares performed in 2023?

Verona Pharma's stock was trading at $26.13 on January 1st, 2023. Since then, VRNA shares have decreased by 22.1% and is now trading at $20.35.
View the best growth stocks for 2023 here
.

When is Verona Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our VRNA earnings forecast
.

How were Verona Pharma's earnings last quarter?

Verona Pharma plc (NASDAQ:VRNA) released its quarterly earnings data on Tuesday, March, 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.06. The business earned $0.46 million during the quarter.

What ETFs hold Verona Pharma's stock?

ETFs with the largest weight of Verona Pharma (NASDAQ:VRNA) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB) and iShares Biotechnology ETF (IBB).

What other stocks do shareholders of Verona Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Trevena (TRVN), Pfizer (PFE), Citius Pharmaceuticals (CTXR), electroCore (ECOR), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV) and Vaxart (VXRT).

When did Verona Pharma IPO?

(VRNA) raised $61 million in an IPO on Thursday, April 27th 2017. The company issued 4,500,000 shares at $13.49 per share. Jefferies and Stifel acted as the underwriters for the IPO and Wedbush PacGrow and SunTrust Robinson Humphrey were co-managers.

What is Verona Pharma's stock symbol?

Verona Pharma trades on the NASDAQ under the ticker symbol "VRNA."

Who are Verona Pharma's major shareholders?

Verona Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (8.35%), Fairmount Funds Management LLC (3.80%), Frazier Life Sciences Management L.P. (3.72%), Jennison Associates LLC (1.36%), Samsara BioCapital LLC (0.92%) and Two Sigma Investments LP (0.69%). Insiders that own company stock include Anders Ullman, Claire Poll, David Zaccardelli, Kathleen A Rickard, Lisa Deschamps, Mark W Hahn, Mark W Hahn, Orbimed Advisors Llc and Patrick John Finn.
View institutional ownership trends
.

How do I buy shares of Verona Pharma?

Shares of VRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Verona Pharma's stock price today?

One share of VRNA stock can currently be purchased for approximately $20.35.

How much money does Verona Pharma make?

Verona Pharma (NASDAQ:VRNA) has a market capitalization of $1.54 billion and generates $460,000.00 in revenue each year. The company earns $-68,700,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

How can I contact Verona Pharma?

Verona Pharma's mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The official website for the company is www.veronapharma.com. The company can be reached via phone at 011-44-0-2032834200 or via email at verona@argotpartners.com.

This page (NASDAQ:VRNA) was last updated on 3/28/2023 by MarketBeat.com Staff